pyrazines has been researched along with pyrazolo(1,5-a)pyrimidine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ashizawa, T; Hoffman, ID; Imada, H; Iwashita, H; Kamiguchi, N; Kawasaki, M; Kokubo, H; Mikami, S; Nakamura, S; Nakashima, K; Nomura, I; Oki, H; Sasaki, S; Suzuki, N; Taniguchi, T; Uchiyama, N; Zou, H | 1 |
1 other study(ies) available for pyrazines and pyrazolo(1,5-a)pyrimidine
Article | Year |
---|---|
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor
Topics: Animals; Brain; Cognition; Cognition Disorders; Crystallography, X-Ray; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 2; Drug Design; Halogenation; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Phosphodiesterase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley | 2017 |